Stem Cells International / 2015 / Article / Tab 3

Clinical Study

Safety of Allogeneic Umbilical Cord Blood Stem Cells Therapy in Patients with Severe Cerebral Palsy: A Retrospective Study

Table 3

Frequency of adverse events after allogeneic UCBSCs treatment.

Type of adverse eventsNumber of reactions (%) Time of occurrence (h)Time of remission (h)

Fever20 (42.6%)19.91 ± 21.7628.62 ± 17.38
Vomiting10 (21.2%)12.00 ± 3.3520.00 ± 6.20
Seizure3 (6.4%)19.50 ± 11.9021.00 ± 6.00
Headache3 (6.4%)11.50 ± 7.7836.00 ± 16.97
Upper respiratory tract infection2 (4.3%)38.50 ± 40.3424.00 ± 0.00
Dermatitis2 (4.3%)12.50 ± 0.7124.96 ± 13.34
Waist pain1 (2.1%)8.0024.00
Constipation1 (2.1%)24.0012.00
Diarrhea0 (0%)
Insomnia0 (0%)
Pneumonia0 (0%)
Anorexia0 (0%)

Note. UCBSCs: umbilical cord blood stem cells; h: hour.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.